RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
You may also be interested in...
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
Novartis hopes its new RNAi-based therapy will be a blockbuster – but must eventually show it can cut heart attacks and cardiovascular deaths.